| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| BioMedicines, Inc. |
| 1301 Marina Village Parkway, Suite 200, Alameda, CA 94501 * (510) 814-0112 |
| Business Description | The company is a biopharmaceutical company that acquires and develops chemical and biological drug products in the areas of cancer, immunology and infectious disease. |
|
Filing Information Not yet | |||
| To Trade As | BIOS (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 11/3/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $50,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| UBS Warburg LLC | Lead Manager | |
| Pacific Crest Securities Inc. | Co-manager | (503) 790-0293 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 9/30/99 | 9/30/00 | ||
| Revenues | - | - | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | -0.178 | -0.857 | -4.520 | -7.684 | -13.246 |
| E.P.S | - | - | -0.830 | -2.220 | -5.440 | -3.350 | -15.000 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -2.20 | -1.46 | -2.96 | ||||
| Cash Flow - Inv. | -7.07 | -5.07 | -0.31 | ||||
| Cash Flow - Fin. | 12.09 | 12.09 | 35.77 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/00 | Financial Ratios | ||||
| Total Assets | 44.23 | Current Assets | 42.53 | Current Ratio | 55.25 |
| Total Liab. | 0.77 | Current Liab. | 0.77 | Debt Ratio | 1.74% |
| Total Equity | 43.46 | Working Cap. | 41.76 | Debt to Equity Ratio | 0.02 |
| Cash | 36.23 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund product development activities, including clinical trials, acquisition of product candidates and working capital and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Dewey Ballantine |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Brentwood Venture Capital affiliated entities | 16.20 | |
| Delphi Ventures affiliated entities | 14.30 | |
| InterWest Partners affiliated entities | 12.50 | |
| Alta Partners affiliated entities | 12.50 | |
| Pictet Global Sectore Fund Biotech | 5.90 | |
| Note: represents ownership of 5% or more prior to the offering. | ||